The Spravato® Buy & Bill model can be incredibly profitable for practices treating patients with treatment-resistant depression, but only if managed correctly.
While providers focus on patient care, behind the scenes, drug acquisition costs and payer reimbursement rates determine whether each treatment adds to your bottom line—or becomes a financial burden.

Many clinics unknowingly overpay for Spravato® due to inconsistent pricing across distributors or poor negotiation strategies. This directly impacts margins and creates unnecessary cash flow strain.

At Finnastra, we specialize in helping practices leverage their purchasing power to negotiate the best possible rates with all four authorized Spravato® distributors, ensuring your practice stays profitable while expanding access to care.

The Challenges of the Spravato® Buy & Bill Model

The Buy & Bill model means your clinic purchases Spravato® upfront, administers it to patients, and then seeks reimbursement from payers. While this model can deliver higher margins, it also comes with significant risks:

  • High upfront costs — Clinics must purchase multiple doses, often totaling $5,000–$10,000+ in inventory.
  • Inconsistent pricing — Each of the four Spravato® distributors may offer different rates, creating unpredictable margins.
  • Delayed reimbursement — Claims denials or slow payer processes can leave practices waiting 30–90 days for payment.
  • Inventory waste — Any denied or unpaid claim means unrecoverable medication costs.

Without a strategic approach to purchasing and billing, these factors can quickly turn a revenue opportunity into a liability.

“We see clinics leaving 15-20% of potential revenue on the table simply because they haven’t optimized their distributor contracts or reimbursement workflows.”
— Leon Stark – Transition Specialist at Finnastra

The Four Spravato® Distributors — and Why Negotiation Matters

Janssen has approved four national distributors for Spravato®:

  1. McKesson Specialty Health
  2. Cardinal Health Specialty
  3. AmerisourceBergen (Besse Medical)
  4. Anda Inc.

Each distributor offers slightly different:

  • Pricing structures
  • Delivery timelines
  • Payment terms
  • Return policies for unused or expired doses

Most clinics work with only one distributor, limiting their ability to comparison shop or negotiate better terms.
When you work with a dedicated Spravato Billing Company like Finnastra, we bring volume-based leverage and industry benchmarks to the negotiation table—something an individual clinic can rarely achieve on its own.

How Finnastra Secures Better Drug Pricing

Our proven strategy combines data, relationships, and negotiation expertise to reduce your cost per dose and protect your margins.

  1. Benchmarking Pricing Across All Distributors

We maintain real-time pricing data from all four distributors and can quickly identify:

  • Which distributor offers the lowest upfront cost
  • Which provides better payment terms (e.g., 30-day float)
  • Which offers the most favorable return policy

Example: One clinic was paying $870 per dose through a single distributor.
After Finnastra’s renegotiation, they dropped to $795 per dose—a 9% cost reduction that added $4,500/month in extra profit.

  1. Volume-Based Negotiation Power

Finnastra represents multiple Spravato® clinics nationwide.
By pooling our clients’ purchasing volume, we negotiate from a position of strength, securing discounts that individual practices simply can’t access.

  1. Aligning Drug Costs with Payer Reimbursement

Lower drug costs mean nothing if your payer reimbursement rates don’t match.
As a full-service Spravato Billing Company, Finnastra also works directly with payers to:

  • Increase allowable rates for Spravato® reimbursement
  • Ensure payment terms align with your distributor’s invoice cycle
  • Prevent underpayments through real-time claim auditing

This holistic approach ensures your practice isn’t caught in a cash flow trap.

Financial Impact: Why This Matters

Consider a practice treating 20 patients per week, each receiving one 84mg dose:

  • Average distributor price (unoptimized): $875 per dose
  • Optimized Finnastra-negotiated price: $800 per dose
  • Savings per treatment: $75

Annual impact:
20 patients × 52 weeks × $75 savings = $78,000/year in additional profit

Now add in reduced claim denials and faster reimbursement, and the total benefit can easily exceed six figures annually.

Why Generic Billing Firms Fail in Buy & Bill

Generic billing companies focus only on submitting claims, leaving your practice vulnerable to:

  • Missed distributor negotiation opportunities
  • Untracked margin erosion
  • Underpayments that go unnoticed until it’s too late
  • Denied claims with no backup financial plan

Our Spravato Billing Services are designed to simplify every aspect of Buy & Bill, from inventory forecasting to payment reconciliation, giving you full visibility and control.

How Finnastra Supports Your Buy & Bill Workflow

When you work with a dedicated Spravato Billing Company like Finnastra, you get:

  1. Distributor Contract Negotiation
    • Lower drug prices
    • Flexible payment terms
    • Favorable return policies
  2. Payer Alignment
    • Optimal reimbursement rates
    • Denial prevention strategies
    • Transparent cash flow reporting
  3. Inventory and Claim Tracking
    • Real-time dashboards showing drug inventory vs. paid claims
    • Early identification of financial gaps
  4. Audit-Proof Documentation
    • Compliance support to pass REMS and payer audits
    • Protection against post-payment clawbacks

Real-World Success Story: $120K Margin Improvement

A mid-sized mental health clinic in New York struggled with:

  • Rising drug costs
  • Frequent payer delays
  • $40,000+ tied up in denied claims

Within 90 days of partnering with Finnastra, we:

  • Lowered their distributor rate by 12%
  • Accelerated reimbursement timelines from 60 days to 25 days
  • Recovered $32,000 in previously denied claims

Total annualized financial improvement: $120,000+

Partner With Finnastra to Optimize Your Spravato® Buy & Bill

Your Spravato® program should be profitable and sustainable, not a source of financial stress.
As a leading Spravato Billing Company, Finnastra ensures every step—from drug purchasing to payer reimbursement—is managed for maximum profitability and compliance.

Our Spravato Billing Services are designed to simplify the Buy & Bill process, protect your margins, and give you peace of mind so you can focus on delivering life-changing care.

Next Step: Secure Better Pricing Today

If your practice is ready to:

  • Lower Spravato® drug costs
  • Eliminate cash flow gaps
  • Maximize Buy & Bill profitability

Contact Finnastra today to schedule a consultation.
Together, we’ll build a strategy that turns every treatment into a sustainable revenue driver.

Learn more: Spravato Billing Services

 

shape
shape

Better Healthcare is Our Mission